Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

MAGNOLIA: Multi-Center, Non-Interventional Extension Study of the Safety and Efficacy of CLS-TA for the Treatment of Macular Edema Associated With Non-Infectious Uveitis

X
Trial Profile

MAGNOLIA: Multi-Center, Non-Interventional Extension Study of the Safety and Efficacy of CLS-TA for the Treatment of Macular Edema Associated With Non-Infectious Uveitis

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 12 Aug 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Triamcinolone (Primary)
  • Indications Retinal oedema; Uveitis
  • Focus Therapeutic Use
  • Acronyms MAGNOLIA
  • Sponsors Clearside Biomedical
  • Most Recent Events

    • 01 Aug 2022 Results assessing extended efficacy and safety of suprachoroidal triamcinolone acetonide injectable suspension among patients with macular oedema secondary to non-infectious uveitis, published in the British Journal of Ophthalmology.
    • 17 May 2021 According to a Clearside Biomedical media release, manuscripts from this study were published in the British Journal of Ophthalmology in March 2021.
    • 03 Mar 2021 Number of cohorts is increased from 1 to 2, by the addition of a cohort for Sham procedure to the existing Suprachoriodal Injection cohort.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top